Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | CDC25B | P30305 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | MAOA | P21397 | 3/20 | 0.43 |
| ▸ | APAF1 | O14727 | 3/20 | 0.43 |
| ▸ | BCHE | P06276 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | BLM | P54132 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | TDP2 | O95551 | 2/20 | 0.43 |
| ▸ | CES2 | O00748 | 2/20 | 0.43 |
| ▸ | CES1 | P23141 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | S100A4 | P26447 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5423240 | 0.71 | CDC25B (0.45) | GSK3BKMT2ACDC25BMEN1POLB | |
| SCHEMBL7993982 | 0.71 | CDC25B (0.45) | GSK3BKMT2ACDC25BMEN1POLB | |
| SCHEMBL551515 | 0.71 | MEN1 (0.45) | GSK3BKMT2ACDC25BMEN1POLB | |
| SCHEMBL7342245 | 0.70 | CDC25B (0.39) | GSK3BKMT2ACDC25BMEN1POLB | |
| SCHEMBL10447642 | 0.65 | KMT2A (0.39) | GSK3BKMT2ACDC25BMEN1POLB | |
| Anthraquinone SCHEMBL4283294 | 0.65 | MEN1 (0.86) | KMT2ACDC25BMEN1POLBKDM4E | |
| Phthalimide SCHEMBL1627400 | 0.65 | GSK3B (0.88) | GSK3BKMT2ACDC25BMEN1POLB | |
| Phthalimide SCHEMBL6342581 | 0.65 | GSK3B (0.88) | GSK3BKMT2ACDC25BMEN1POLB | |
| Phthalimide SCHEMBL5970009 | 0.65 | GSK3B (0.88) | GSK3BKMT2ACDC25BMEN1POLB | |
| Anthraquinone SCHEMBL1901249 | 0.63 | MEN1 (1.00) | KMT2ACDC25BMEN1POLBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2813502-B1 | Bradykinin receptor antagonists and pharmaceutical compositions containing them | DOMPÉ FARM S P A (IT) | 2017-01-04 | — | — | EP | claimed |
| US-9409876-B2 | Bradykinin receptor antagonists and pharmaceutical compositions containing them | DOMPE' FARMACEUTICI S.P.A. (IT) | 2016-08-09 | — | — | US | claimed |
| US-20140371274-A1 | BRADYKININ RECEPTOR ANTAGONISTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE' FARMACEUTICI S.P.A. (IT) | 2014-12-18 | — | — | US | claimed |
| EP-2813502-A1 | Bradykinin receptor antagonists and pharmaceutical compositions containing them | Dompe' S.p.A. (IT) | 2014-12-17 | — | — | EP | claimed |
| EP-2813502-B1 | Bradykinin receptor antagonists and pharmaceutical compositions containing them | DOMPÉ FARM S P A (IT) | 2017-01-04 | — | — | EP | disclosed |
| US-9409876-B2 | Bradykinin receptor antagonists and pharmaceutical compositions containing them | DOMPE' FARMACEUTICI S.P.A. (IT) | 2016-08-09 | — | — | US | disclosed |
| US-20140371274-A1 | BRADYKININ RECEPTOR ANTAGONISTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE' FARMACEUTICI S.P.A. (IT) | 2014-12-18 | — | — | US | disclosed |
| EP-2813502-A1 | Bradykinin receptor antagonists and pharmaceutical compositions containing them | Dompe' S.p.A. (IT) | 2014-12-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371274-A1 | BRADYKININ RECEPTOR ANTAGONISTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BDKRB1, BDKRB2, EDNRB | GSK3B 2446/4885KMT2A 3540/4885CDC25B 3343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.